-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14

Benzinga·10/27/2026 13:23:06
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.